Girard Sharp LLP is investigating potential claims on behalf of investors who purchased or otherwise acquired Waldencast stock prior to July 7, 2023.
If you acquired Waldencast stock and would like to discuss your potential claim, please fill out our form or call (866) 981-4800 for a free consultation with a Girard Sharp attorney.
More About the Waldencast Investigation
On July 5, 2023, Waldencast announced that certain of Obagi’s financial statements for periods prior to the merger transaction “should no longer be relied upon.” The financial statements containing errors and requiring restatement included those for 2021 and for the first quarter of 2022. These financial statements were included within Waldencast’s registration and proxy statement soliciting stockholder approval of the merger.
On the news of the restatement, the price of Waldencast stock declined by approximately 10% on July 6, 2023. And since the merger with Obagi on July 27, 2022, the stock price has declined by approximately 25%.
If you acquired Waldencast stock, fill out the form above to speak to a Girard Sharp attorney about your rights.
Our Commitment to Excellence
Girard Sharp represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We serve on the Plaintiffs’ executive committee in the recent spoofing litigation against JPMorgan Chase that settled for $60 million, a favorable resolution that the district court preliminarily approved in December 2021. Our attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal.
